— Know what they know.
Not Investment Advice

SIOX NASDAQ

Sio Gene Therapies Inc.
1W: +22.9% 1M: +22.9% 3M: +21.0% 1Y: +4.9% 3Y: -83.5% 5Y: -94.9%
$0.48
Last traded 2024-02-07 — delisted
NASDAQ · Healthcare · Biotechnology

Cash Flow Trends

Operating Cash Flow
-$60M -29.5% ▼
Capital Expenditures
$695K -74.6% ▼
5Y CAGR: +45.9%
Free Cash Flow
-$61M -29.9% ▼
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
-$55M -240.2% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2018FY2019FY2020FY2021FY2022
— Operating Activities —
Net Income-$222M-$129M-$73M-$32M-$72M
Depreciation & Amort.$3M$2M$3M$2M$666K
Stock-Based Comp.$32M$16M$8M$4M$7M
Change in Working Capital-$4M-$19M-$3M-$9M$4M
Other Non-Cash Items-$3M-$5M-$2M-$782K-$410K
Operating Cash Flow-$190M-$134M-$67M-$47M-$60M
— Investing Activities —
Capital Expenditures-$4M-$202K-$255K-$398K-$695K
Acquisitions (Net)$0$0$0$0$0
Investment Purchases$0$0$0$0$0
Investment Sales$0$0$0$13M$4M
Other Investing$0$0$0$0$0
Investing Cash Flow-$4M-$202K-$255K$12M$4M
— Financing Activities —
Net Debt Issuance$0$0$0$0$0
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$136M$87M$41M$74M$1M
Financing Cash Flow$136M$87M$41M$74M$1M
Net Change in Cash-$58M-$47M-$26M$39M-$55M
Cash End of Period$154M$107M$81M$120M$65M
Free Cash Flow-$195M-$134M-$68M-$47M-$61M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms